MYNX CONTROL Vascular Closure Device

The outstanding design and predictable deployment of MYNX CONTROL™ Vascular Closure Device delivers outstanding performance and control, for reliable secure arterial closures.

This website contains information on products for a wide range of countries. As a result, it may contain information about products not available in your country. For more information, please contact your local Cordis representative.

Product Description

MYNX CONTROL Vascular Closure Device integrates active extravascular sealing and resorbability properties with a next-generation delivery system to maximize predictability, safety, and ease of use in sealing 5-7F femoral arterial access sites.

Featuring:

  • A next-generation deployment system designed for predictability and ease of use with a 2-button streamline procedural steps
  • A sheath catch compatible with the procedural sheath
  • A tension indicator providing visual confirmation of device position for proper sealant deployment
  • Available in 5F, 6F, and 7F sizes

MYNX VCD has been clinically proven to reduce surgical complications, expedite recovery, shorten hospital stays, and increase patient comfort (1-5).

1Pruski MJ Jr et al. MynxGrip for closure of antegrade puncture after peripheral interventions with same-day discharge. Vasc Endovasc Surg. 2017 Feb;51(2):67-71.
2Baker NC et al. Active versus passive anchoring vascular closure devices following percutaneous coronary intervention: a safety and efficacy comparative analysis. J Interv Cardiol. 2016 Feb; 29(1): 108-112.
3Hutchings D et al. Success, safety, and efficacy of the Mynx femoral closure device in a real-world cohort: single-center experience. J Invasive Cardiol. 2016 Mar;28(3):104-108.
4 Noor S et al. Successful reduction of surgeries secondary to arterial access site complications: a retrospective review at a single center with an extravascular closure device. Vasc Endovascular Surg. 2010 Jul;44(5):345-349.
5 Fargen KM et al. A prospective randomized single-blind trial of patient comfort following vessel closure: extravascular synthetic sealant closure provides less pain than a self-tightening suture

  1. (Abstract) Mynx Vascular Closure Device Achieves Reliable Closure and Hemostasis of Percutaneous Transfemoral Venous Access in a Porcine Vascular Model
    S. Sanjay Srivatsa, MBBChir1; Arjun Srivatsa1; Taylor A. Spangler, DVM, DACVP2. The Journal of Invasive Cardiology. February 201
  2. The MYNXGRIP™ Vascular Closure Device
    Hoang Minh Thai, MD, FACC, FSCAI, and Barry S. Weinstock, MD. Endovascular Today. April 2012.
  3. (Abstract) Successful Reduction of Surgeries Secondary to Arterial Access Site Complications
    A Retrospective Review at a Single-Center with an Extravascular Closure Device.
    Noor S, Meyers S, Curl R. Vascular and Endovascular Surgery. May 2010;44(5):345-9.
  4. (Abstract) A Prospective Randomized Single-blind trial of Patient Comfort Following Vessel Closure
    Extravascular Synthetic Sealant Closure Provides Less Pain than a Self-tightening Suture Vascular Compression Device.
    Fargen KM, Hoh BL, Mocco J. J Neurointerv Surg. 2011;3(3):219-23
  5. Mynx Vascular Closure Device Early Ambulation Study
    Vikranth R. Gongidi, DO; Ahsan Jafir, DO; and Vijay Verma, MD, FACC, FSCAI. Endovascular Today. October 2013
  6. (Abstract) Occurrence of angiographic femoral artery complications after vascular closure with Mynx and AngioSeal
    Fargen KM, Velat GJ, Lawson MF, et al. Journal of Neurolnterventional Surgery. 2013;5(2):161-4
  7. Use of Vascular Closure Device After Access of Common Femoral Artery Through an Existing Stent
    George JC. Vascular Disease Management. 2012;9(5):E68-E70.
  8. Two Years of Extravascular Closure With the Mynx™ Vascular Closure Device
    The Baptist Memorial Hospital experience revisited.
    David Wolford, MD, FACC. Endovascular Today. August 2010.
  9. Why Extravascular Closure?
    The Baptist Memorial Hospital Experience with the Mynx Vascular Closure Device
    David Wolford, MD, FACC. Endovascular Today. August 2009.
  10. (Abstract) The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Vascular Closure
    Initial Clinical Results for Mynx. D. Scheinert MD et al. Catheterization and Cardiovascular Interventions. November 2007.


The MYNX CONTROL™ VCD includes:

  • (1) MYNX CONTROL™ VCD including balloon catheter and integrated polyethylene glycol sealant
  • (1) 10 ml locking syringe
ProductSizeOrder Number

MYNX CONTROL™ VCD

5FMX5060E
MYNX CONTROL™ VCD6F / 7FMX6760E

*Order Numbers are only valid for Europe, Middle East, and Africa.

IFU

Please refer to the Instructions for Use for complete information, including indications, precautions, warnings, and potential adverse events.

Customer Service and Ordering Information

If you are located in Australia, China, India, Japan or Korea, please direct your order or question directly to your country’s contact.